Acta Neuropathologica

, Volume 125, Issue 5, pp 621–636 | Cite as

What do we know about IDH1/2 mutations so far, and how do we use it?

  • Craig HorbinskiEmail author


Whole genome analyses have facilitated the discovery of clinically relevant genetic alterations in a variety of diseases, most notably cancer. A prominent example of this was the discovery of mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) in a sizeable proportion of gliomas and some other neoplasms. Herein the normal functions of these enzymes, how the mutations alter their catalytic properties, the effects of their d-2-hydroxyglutarate metabolite, technical considerations in diagnostic neuropathology, implications about prognosis and therapeutic considerations, and practical applications and controversies regarding IDH1/2 mutation testing are discussed.


IDH1/2 2-Hydroxyglutarate Glioma Histone Methylation 



CH was supported by National Cancer Institute K08 CA155764-01A1, National Institute of General Medical Sciences 2P20 RR020171, and the University of Kentucky College of Medicine Physician Scientist Program.

Supplementary material

401_2013_1106_MOESM1_ESM.doc (40 kb)
Supplementary material 1 (DOC 40 kb)


  1. 1.
    Abbas S, Lugthart S, Kavelaars FG et al (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116(12):2122–2126PubMedGoogle Scholar
  2. 2.
    Aghili M, Zahedi F, Rafiee E (2009) Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol 91:233–236PubMedGoogle Scholar
  3. 3.
    Ahmad K, Henikoff S (2002) The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell 9(6):1191–1200PubMedGoogle Scholar
  4. 4.
    Ahmadi R, Stockhammer F, Becker N et al (2012) No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 109(1):15–22PubMedGoogle Scholar
  5. 5.
    Akalin A, Garrett-Bakelman FE, Kormaksson M et al (2012) Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 8(6):e1002781PubMedGoogle Scholar
  6. 6.
    Amary MF, Bacsi K, Maggiani F et al (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224(3):334–343PubMedGoogle Scholar
  7. 7.
    Amary MF, Damato S, Halai D et al (2011) Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43(12):1262–1265PubMedGoogle Scholar
  8. 8.
    Andronesi OC, Kim GS, Gerstner E et al (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4(116):116ra4PubMedGoogle Scholar
  9. 9.
    Atai NA, Renkema-Mills NA, Bosman J et al (2011) Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem 59(5):489–503PubMedGoogle Scholar
  10. 10.
    Atkinson SP, Hoare SF, Glasspool RM, Keith WN (2005) Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65(17):7585–7590PubMedGoogle Scholar
  11. 11.
    Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602PubMedGoogle Scholar
  12. 12.
    Balss J, Pusch S, Beck AC et al (2012) Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol 124(6):883–891PubMedGoogle Scholar
  13. 13.
    Bettegowda C, Agrawal N, Jiao Y et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333(6048):1453–1455PubMedGoogle Scholar
  14. 14.
    Bleeker FE, Atai NA, Lamba S et al (2010) The prognostic IDH1 (R132) mutation is associated with reduced NADP + dependent IDH activity in glioblastoma. Acta Neuropathol 119(4):487–494PubMedGoogle Scholar
  15. 15.
    Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30(1):7–11PubMedGoogle Scholar
  16. 16.
    Boisselier B, Gallego Perez-Larraya J, Rossetto M et al (2012) Detection of IDH1 mutation in the plasma of patients with glioma. Neurology 79(16):1693–1698PubMedGoogle Scholar
  17. 17.
    Borger DR, Tanabe KK, Fan KC et al (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17(1):72–79PubMedGoogle Scholar
  18. 18.
    Bralten LB, Kloosterhof NK, Balvers R et al (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 69(3):455–463PubMedGoogle Scholar
  19. 19.
    Brauburger K, Burckhardt G, Burckhardt BC (2011) The sodium-dependent di- and tricarboxylate transporter, NaCT, is not responsible for the uptake of d-, l-2-hydroxyglutarate and 3-hydroxyglutarate into neurons. J Inherit Metab Dis 34(2):477–482PubMedGoogle Scholar
  20. 20.
    Brehmer S, Pusch S, Schmieder K, von Deimling A, Hartmann C (2011) Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. Neuropathol Appl Neurobiol 37(3):330–332PubMedGoogle Scholar
  21. 21.
    Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119(4):509–511PubMedGoogle Scholar
  22. 22.
    Capper D, Reuss D, Schittenhelm J et al (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121(2):241–252PubMedGoogle Scholar
  23. 23.
    Capper D, Simon M, Langhans CD et al (2011) 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 131(3):766–768PubMedGoogle Scholar
  24. 24.
    Capper D, Weissert S, Balss J et al (2009) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245–254PubMedGoogle Scholar
  25. 25.
    Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601PubMedGoogle Scholar
  26. 26.
    Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33(7):1349–1355PubMedGoogle Scholar
  27. 27.
    Chalmers RA, Lawson AM, Watts RW et al (1980) d-2-hydroxyglutaric aciduria: case report and biochemical studies. J Inherit Metab Dis 3(1):11–15PubMedGoogle Scholar
  28. 28.
    Choi C, Ganji SK, DeBerardinis RJ et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624–629PubMedGoogle Scholar
  29. 29.
    Chou WC, Lei WC, Ko BS et al (2011) The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25(2):246–253PubMedGoogle Scholar
  30. 30.
    Chowdhury R, Yeoh KK, Tian YM et al (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12(5):463–469PubMedGoogle Scholar
  31. 31.
    Christensen BC, Smith AA, Zheng S et al (2011) DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103(2):143–153PubMedGoogle Scholar
  32. 32.
    Clark K, Voronovich Z, Horbinski C (2013) How molecular testing can help (and hurt) in the workup of gliomas. Am J Clin Pathol 139(3):275–288PubMedGoogle Scholar
  33. 33.
    Clark KH, Villano JL, Nikiforova MN, Hamilton RL, Horbinski C (2013) 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol. doi: 10.1111/nan.12031 PubMedGoogle Scholar
  34. 34.
    Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739–744PubMedGoogle Scholar
  35. 35.
    DeGregori J (2011) Evolved tumor suppression: why are we so good at not getting cancer? Cancer Res 71(11):3739–3744PubMedGoogle Scholar
  36. 36.
    Desestret V, Ciccarino P, Ducray F et al (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105(2):219–224PubMedGoogle Scholar
  37. 37.
    Diehn M, Cho RW, Lobo NA et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780–783PubMedGoogle Scholar
  38. 38.
    Dubbink HJ, Taal W, van Marion R et al (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73(21):1792–1795PubMedGoogle Scholar
  39. 39.
    Ducray F, El Hallani S, Idbaih A (2009) Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 21(6):537–542PubMedGoogle Scholar
  40. 40.
    Duncan CG, Barwick BG, Jin G et al (2012) A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 22(12):2339–2355PubMedGoogle Scholar
  41. 41.
    Dunham MA, Neumann AA, Fasching CL, Reddel RR (2000) Telomere maintenance by recombination in human cells. Nat Genet 26(4):447–450PubMedGoogle Scholar
  42. 42.
    Duran M, Kamerling JP, Bakker HD, van Gennip AH, Wadman SK (1980) l-2-Hydroxyglutaric aciduria: an inborn error of metabolism? J Inherit Metab Dis 3(4):109–112PubMedGoogle Scholar
  43. 43.
    Elkhaled A, Jalbert LE, Phillips JJ et al (2012) Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 4(116):116ra5PubMedGoogle Scholar
  44. 44.
    Ellezam B, Theeler BJ, Walbert T et al (2012) Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathol 124(3):449–451PubMedGoogle Scholar
  45. 45.
    Fathi AT, Sadrzadeh H, Borger DR et al (2012) Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 120(23):4649–4652PubMedGoogle Scholar
  46. 46.
    Felsberg J, Wolter M, Seul H et al (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119(4):501–507PubMedGoogle Scholar
  47. 47.
    Figueroa ME, Abdel-Wahab O, Lu C et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553–567PubMedGoogle Scholar
  48. 48.
    Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW (2012) Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 25(3):375–383PubMedGoogle Scholar
  49. 49.
    Gaal J, Burnichon N, Korpershoek E et al (2010) Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95(3):1274–1278PubMedGoogle Scholar
  50. 50.
    Glas M, Bahr O, Felsberg J et al (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 70(3):445–453PubMedGoogle Scholar
  51. 51.
    Gorovets D, Kannan K, Shen R et al (2012) IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 18(9):2490–2501PubMedGoogle Scholar
  52. 52.
    Goze C, Bezzina C, Goze E et al (2012) 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol 108(1):69–75PubMedGoogle Scholar
  53. 53.
    Gravendeel LA, Kloosterhof NK, Bralten LB et al (2010) Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31(3):E1186–E1199PubMedGoogle Scholar
  54. 54.
    Gravendeel LA, Kouwenhoven MC, Gevaert O et al (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69(23):9065–9072PubMedGoogle Scholar
  55. 55.
    Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE (2010) The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116(15):2779–2782PubMedGoogle Scholar
  56. 56.
    Gross S (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344PubMedGoogle Scholar
  57. 57.
    Gupta R, Flanagan S, Li CC et al (2013) Expanding the spectrum of IDH1 mutations in gliomas. Mod Pathol. doi: 10.1038/modpathol.2012.210 PubMedGoogle Scholar
  58. 58.
    Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718PubMedGoogle Scholar
  59. 59.
    Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474PubMedGoogle Scholar
  60. 60.
    Hegi ME (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedGoogle Scholar
  61. 61.
    Horbinski C (2012) Something old and something new about molecular diagnostics in gliomas. In: Hunt JL (ed) Surgical pathology clinics: molecular oncology. Elsevier, Philadelphia, pp 919–939Google Scholar
  62. 62.
    Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN (2010) Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 12(4):487–492PubMedGoogle Scholar
  63. 63.
    Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN (2009) Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68:1319–1325PubMedGoogle Scholar
  64. 64.
    Horbinski C, Kofler J, Yeaney G et al (2011) Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 21(5):564–574PubMedGoogle Scholar
  65. 65.
    Houillier C, Wang X, Kaloshi G et al (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75(17):1560–1566PubMedGoogle Scholar
  66. 66.
    Ichimura K (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341–347PubMedGoogle Scholar
  67. 67.
    Jenkins RB, Xiao Y, Sicotte H et al (2012) A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 44(10):1122–1125PubMedGoogle Scholar
  68. 68.
    Jin G, Reitman ZJ, Duncan CG et al (2013) Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 73(2):496–501PubMedGoogle Scholar
  69. 69.
    Jin G, Reitman ZJ, Spasojevic I et al (2011) 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 6(2):e16812PubMedGoogle Scholar
  70. 70.
    Jo SH, Lee SH, Chun HS et al (2002) Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase. Biochem Biophys Res Commun 292(2):542–549PubMedGoogle Scholar
  71. 71.
    Jo SH, Son MK, Koh HJ et al (2001) Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP + -dependent isocitrate dehydrogenase. J Biol Chem 276(19):16168–16176PubMedGoogle Scholar
  72. 72.
    Jones DT, Mulholland SA, Pearson DM et al (2011) Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathol 121(6):753–761PubMedGoogle Scholar
  73. 73.
    Joseph NM, Phillips J, Dahiya S et al (2012) Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Mod Pathol 26(3):315–326PubMedGoogle Scholar
  74. 74.
    Juratli TA, Kirsch M, Geiger K et al (2012) The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol 110(3):325–333PubMedGoogle Scholar
  75. 75.
    Juratli TA, Kirsch M, Robel K et al (2012) IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 108(3):403–410PubMedGoogle Scholar
  76. 76.
    Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D (2013) Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol [Epub ahead of print]Google Scholar
  77. 77.
    Kang MR, Kim MS, Oh JE et al (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125(2):353–355PubMedGoogle Scholar
  78. 78.
    Kannan K, Inagaki A, Silber J et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3(10):1194–1203PubMedGoogle Scholar
  79. 79.
    Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27 M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439–447PubMedGoogle Scholar
  80. 80.
    Kil IS, Huh TL, Lee YS, Lee YM, Park JW (2006) Regulation of replicative senescence by NADP + -dependent isocitrate dehydrogenase. Free Radic Biol Med 40(1):110–119PubMedGoogle Scholar
  81. 81.
    Kil IS, Kim SY, Lee SJ, Park JW (2007) Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs. Free Radic Biol Med 43(8):1197–1207PubMedGoogle Scholar
  82. 82.
    Kil IS, Lee JH, Shin AH, Park JW (2004) Glycation-induced inactivation of NADP(+)-dependent isocitrate dehydrogenase: implications for diabetes and aging. Free Radic Biol Med 37(11):1765–1778PubMedGoogle Scholar
  83. 83.
    Kim J, Kim JI, Jang HS, Park JW, Park KM (2011) Protective role of cytosolic NADP(+)-dependent isocitrate dehydrogenase, IDH1, in ischemic pre-conditioned kidney in mice. Free Radic Res 45(7):759–766PubMedGoogle Scholar
  84. 84.
    Kim YH, Nobusawa S, Mittelbronn M et al (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177(6):2708–2714PubMedGoogle Scholar
  85. 85.
    Kim YH, Pierscianek D, Mittelbronn M et al (2011) TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 64(10):850–852PubMedGoogle Scholar
  86. 86.
    Kipp BR, Voss JS, Kerr SE et al (2012) Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 43(10):1552–1558PubMedGoogle Scholar
  87. 87.
    Koivunen P, Lee S, Duncan CG et al (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483(7390):484–488PubMedGoogle Scholar
  88. 88.
    Korshunov A, Meyer J, Capper D et al (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118(3):401–405PubMedGoogle Scholar
  89. 89.
    Koszarska M, Bors A, Feczko A et al (2012) Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leuk Lymphoma [Epub ahead of print]Google Scholar
  90. 90.
    Kranendijk M, Struys EA, van Schaftingen E et al (2010) IDH2 mutations in patients with d-2-hydroxyglutaric aciduria. Science 330(6002):336PubMedGoogle Scholar
  91. 91.
    Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C (2011) Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One 6(5):e19868PubMedGoogle Scholar
  92. 92.
    Labussiere M, Idbaih A, Wang XW et al (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74(23):1886–1890PubMedGoogle Scholar
  93. 93.
    Laffaire J, Everhard S, Idbaih A et al (2011) Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 13(1):84–98PubMedGoogle Scholar
  94. 94.
    Lai A, Kharbanda S, Pope WB et al (2012) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29(34):4482–4490Google Scholar
  95. 95.
    Lass U, Numann A, von Eckardstein K et al (2012) Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS One 7(7):e41298PubMedGoogle Scholar
  96. 96.
    Latini A, da Silva CG, Ferreira GC et al (2005) Mitochondrial energy metabolism is markedly impaired by d-2-hydroxyglutaric acid in rat tissues. Mol Genet Metab 86(1–2):188–199PubMedGoogle Scholar
  97. 97.
    Latini A, Scussiato K, Rosa RB et al (2003) d-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur J Neurosci 17(10):2017–2022PubMedGoogle Scholar
  98. 98.
    Lazovic J, Soto H, Piccioni D et al (2012) Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol 14(12):1465–1472PubMedGoogle Scholar
  99. 99.
    Lee JH, Kim SY, Kil IS, Park JW (2007) Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+dependent isocitrate dehydrogenase. J Biol Chem 282(18):13385–13394PubMedGoogle Scholar
  100. 100.
    Lee SM, Huh TL, Park JW (2001) Inactivation of NADP(+)-dependent isocitrate dehydrogenase by reactive oxygen species. Biochimie 83(11–12):1057–1065PubMedGoogle Scholar
  101. 101.
    Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW (2002) Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32(11):1185–1196PubMedGoogle Scholar
  102. 102.
    Lee SM, Park SY, Shin SW, Kil IS, Yang ES, Park JW (2009) Silencing of cytosolic NADP(+)-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine. Free Radic Res 43(2):165–173PubMedGoogle Scholar
  103. 103.
    Leonardi R, Subramanian C, Jackowski S, Rock CO (2012) Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 287(18):14615–14620PubMedGoogle Scholar
  104. 104.
    Leu S, von Felten S, Frank S et al (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol [Epub ahead of print]Google Scholar
  105. 105.
    Li S, Chou AP, Chen W et al (2013) Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol 15(1):57–68PubMedGoogle Scholar
  106. 106.
    Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124(5):615–625PubMedGoogle Scholar
  107. 107.
    Lopez GY, Reitman ZJ, Solomon D et al (2010) IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 398(3):585–587PubMedGoogle Scholar
  108. 108.
    Losman JA, Looper R, Koivunen P et al (2013) (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. Science [Epub ahead of print]Google Scholar
  109. 109.
    Loussouarn D, Le Loupp AG, Frenel JS et al (2012) Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 40(6):2058–2062PubMedGoogle Scholar
  110. 110.
    Lovejoy CA, Li W, Reisenweber S et al (2012) Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8(7):e1002772PubMedGoogle Scholar
  111. 111.
    Lu C, Ward PS, Kapoor GS et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390):474–478PubMedGoogle Scholar
  112. 112.
    Luchman HA, Stechishin OD, Dang NH et al (2012) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 14(2):184–191PubMedGoogle Scholar
  113. 113.
    Malmstrom A, Gronberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926 (Epub 2012 Aug 8)PubMedGoogle Scholar
  114. 114.
    Marcucci G, Maharry K, Wu YZ et al (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28(14):2348–2355PubMedGoogle Scholar
  115. 115.
    McDonald KL, McDonnell J, Muntoni A et al (2010) Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 69(7):729–736PubMedGoogle Scholar
  116. 116.
    Metallo CM, Gameiro PA, Bell EL et al (2011) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481(7381):380–384PubMedGoogle Scholar
  117. 117.
    Metellus P, Colin C, Taieb D et al (2011) IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol 105(3):591–600PubMedGoogle Scholar
  118. 118.
    Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729PubMedGoogle Scholar
  119. 119.
    Meyer J, Pusch S, Balss J et al (2010) PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20(2):298–300PubMedGoogle Scholar
  120. 120.
    Mukasa A, Takayanagi S, Saito K et al (2011) The significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci 2:1349–7006Google Scholar
  121. 121.
    Mulholland S, Pearson DM, Hamoudi RA et al (2012) MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int J Cancer 131(5):1104–1113PubMedGoogle Scholar
  122. 122.
    Mullen AR, Wheaton WW, Jin ES et al (2011) Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481(7381):385–388PubMedGoogle Scholar
  123. 123.
    Muller T, Gessi M, Waha A et al (2012) Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol 181(2):675–683PubMedGoogle Scholar
  124. 124.
    Nguyen DN, Heaphy CM, de Wilde RF et al (2012) Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high grade astrocytomas. Brain Pathol 29:1750–3639Google Scholar
  125. 125.
    Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007PubMedGoogle Scholar
  126. 126.
    Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522PubMedGoogle Scholar
  127. 127.
    Okita Y, Narita Y, Miyakita Y et al (2012) IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol. doi: 10.3892/ijo.2012.1564
  128. 128.
    Olar A, Raghunathan A, Albarracin CT et al (2012) Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann Diagn Pathol 16(3):161–170PubMedGoogle Scholar
  129. 129.
    Pang B, Durso MB, Hamilton RL, Nikiforova MN (2013) A novel cold-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas. Diagn Mol Pathol 22(1):28–34PubMedGoogle Scholar
  130. 130.
    Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812PubMedGoogle Scholar
  131. 131.
    Patel JP, Gonen M, Figueroa ME et al (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079–1089PubMedGoogle Scholar
  132. 132.
    Patnaik MM, Hanson CA, Hodnefield JM et al (2011) Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a mayo clinic study of 277 patients. Leukemia 26(1):101–105PubMedGoogle Scholar
  133. 133.
    Perez C, Martinez-Calle N, Martin-Subero JI et al (2012) TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One 7(2):e31605PubMedGoogle Scholar
  134. 134.
    Pietrak B, Zhao H, Qi H et al (2011) A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of alpha HG. Biochemistry 50(21):4804–4812PubMedGoogle Scholar
  135. 135.
    Pollack IF, Hamilton RL, Sobol RW et al (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Childs Nerv Syst 27(1):87–94PubMedGoogle Scholar
  136. 136.
    Preusser M, Hoeftberger R, Woehrer A et al (2012) Prognostic value of Ki67 index in anaplastic oligodendroglial tumours—a translational study of the European organization for research and treatment of cancer brain tumor group. Histopathology 60(6):885–894PubMedGoogle Scholar
  137. 137.
    Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B, Hainfellner JA (2011) Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 70(8):715–723PubMedGoogle Scholar
  138. 138.
    Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A (2011) Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37(4):428–430PubMedGoogle Scholar
  139. 139.
    Qi ST, Yu L, Lu YT et al (2011) IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep 26(6):1479–1485PubMedGoogle Scholar
  140. 140.
    Reitman ZJ, Jin G, Karoly ED et al (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 108(8):3270–3275PubMedGoogle Scholar
  141. 141.
    Rice T, Zheng S, Decker PA et al (2013) Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro Oncol [Epub ahead of print]Google Scholar
  142. 142.
    Royds JA, Al Nadaf S, Wiles AK et al (2011) The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One 6(10):e26737PubMedGoogle Scholar
  143. 143.
    Sahm F, Capper D, Jeibmann A et al (2012) Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol 69(4):523–526PubMedGoogle Scholar
  144. 144.
    Sahm F, Koelsche C, Meyer J et al (2012) CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 123(6):853–860PubMedGoogle Scholar
  145. 145.
    Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154PubMedGoogle Scholar
  146. 146.
    Sasaki M, Knobbe CB, Itsumi M et al (2012) d-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26(18):2038–2049PubMedGoogle Scholar
  147. 147.
    Sasaki M, Knobbe CB, Munger JC et al (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488(7413):656–659PubMedGoogle Scholar
  148. 148.
    Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231PubMedGoogle Scholar
  149. 149.
    Seiz M, Tuettenberg J, Meyer J et al (2010) Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 120(2):261–267PubMedGoogle Scholar
  150. 150.
    Sellner L, Capper D, Meyer J et al (2010) Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. Eur J Haematol 85(5):457–459PubMedGoogle Scholar
  151. 151.
    Seltzer MJ, Bennett BD, Joshi AD et al (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70(22):8981–8987PubMedGoogle Scholar
  152. 152.
    Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N (2011) Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol 178(3):1395–1402PubMedGoogle Scholar
  153. 153.
    Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797):268–274PubMedGoogle Scholar
  154. 154.
    Songtao Q, Lei Y, Si G et al (2011) IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103(2):269–273PubMedGoogle Scholar
  155. 155.
    Steenweg ME, Jakobs C, Errami A et al (2010) An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat 31(4):380–390PubMedGoogle Scholar
  156. 156.
    Stockhammer F, Misch M, Helms HJ et al (2012) IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 21(3):194–197PubMedGoogle Scholar
  157. 157.
    Struys EA (2006) d-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect. J Inherit Metab Dis 29(1):21–29PubMedGoogle Scholar
  158. 158.
    Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437PubMedGoogle Scholar
  159. 159.
    Taal W, Dubbink HJ, Zonnenberg CB et al (2011) First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol 13(2):235–241PubMedGoogle Scholar
  160. 160.
    Tabatabai G, Hegi M, Stupp R, Weller M (2012) Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Curr Neurol Neurosci Rep 12(3):302–307PubMedGoogle Scholar
  161. 161.
    Takano S, Kato Y, Yamamoto T et al (2012) Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108(3):361–373PubMedGoogle Scholar
  162. 162.
    Takeuchi T, Watanabe Y, Takano-Shimizu T, Kondo S (2006) Roles of jumonji and jumonji family genes in chromatin regulation and development. Dev Dyn 235(9):2449–2459PubMedGoogle Scholar
  163. 163.
    Tefferi A, Jimma T, Sulai NH et al (2011) IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26(3):475–480PubMedGoogle Scholar
  164. 164.
    Thon N, Eigenbrod S, Kreth S et al (2012) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118(2):452–460PubMedGoogle Scholar
  165. 165.
    Tian X, Fang J (2007) Current perspectives on histone demethylases. Acta Biochim Biophys Sin (Shanghai) 39(2):81–88Google Scholar
  166. 166.
    Toedt G, Barbus S, Wolter M et al (2011) Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 128(5):1095–1103PubMedGoogle Scholar
  167. 167.
    Turcan S, Rohle D, Goenka A et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390):479–483PubMedGoogle Scholar
  168. 168.
    van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344–350PubMedGoogle Scholar
  169. 169.
    van den Bent MJ, Hartmann C, Preusser M et al (2013) Interlaboratory comparison of IDH mutation detection. J Neurooncol [Epub ahead of print]Google Scholar
  170. 170.
    Vissers LE, Fano V, Martinelli D et al (2011) Whole-exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with d-2-hydroxyglutaric aciduria (MC-HGA). Am J Med Genet A 155A(11):2609–2616PubMedGoogle Scholar
  171. 171.
    Wagner K, Damm F, Gohring G et al (2012) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28(14):2356–2364Google Scholar
  172. 172.
    Walker EJ, Zhang C, Castelo-Branco P et al (2012) Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. Cancer Res 72(3):636–644PubMedGoogle Scholar
  173. 173.
    Wang XW, Boisselier B, Rossetto M et al (2012) Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas. Cancer 119(4):806–813PubMedGoogle Scholar
  174. 174.
    Ward PS, Cross JR, Lu C et al (2012) Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31(19):2491–2498PubMedGoogle Scholar
  175. 175.
    Ward PS, Lu C, Cross JR et al (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288(6):3804–3815PubMedGoogle Scholar
  176. 176.
    Ward PS, Patel J, Wise DR et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17(3):225–234PubMedGoogle Scholar
  177. 177.
    Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153PubMedGoogle Scholar
  178. 178.
    Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H (2009) Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117:653–656PubMedGoogle Scholar
  179. 179.
    Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27(34):5743–5750PubMedGoogle Scholar
  180. 180.
    Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874–5880PubMedGoogle Scholar
  181. 181.
    Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, von Deimling A, Zagzag D (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 alpha upregulation in adult glioma. Acta Neuropathol 121(2):279–281PubMedGoogle Scholar
  182. 182.
    Wise DR, Ward PS, Shay JE et al (2011) Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 108(49):19611–19616PubMedGoogle Scholar
  183. 183.
    Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253PubMedGoogle Scholar
  184. 184.
    Xu W, Yang H, Liu Y et al (2010) Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of alpha-Ketoglutarate-Dependent Dioxygenases. Cancer Cell 19(1):17–30Google Scholar
  185. 185.
    Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773PubMedGoogle Scholar
  186. 186.
    Yang B, Zhong C, Peng Y, Lai Z, Ding J (2010) Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H. Cell Res 20(11):1188–1200PubMedGoogle Scholar
  187. 187.
    Yazici N, Sarialioglu F, Alkan O, Kayaselcuk F, Erol I (2009) Glutaric aciduria type II [corrected] and brain tumors: a case report and review of the literature. J Pediatr Hematol Oncol 31(11):865–869PubMedGoogle Scholar
  188. 188.
    Yen KE, Bittinger MA, Su SM, Fantin VR (2010) Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29(49):6409–6417PubMedGoogle Scholar
  189. 189.
    Yip S, Butterfield YS, Morozova O et al (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 226(1):7–16PubMedGoogle Scholar
  190. 190.
    Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324(5924):261–265PubMedGoogle Scholar
  191. 191.
    Zhu J, Cui G, Chen M et al (2012) Expression of R132H Mutational IDH1 in Human U87 Glioblastoma Cells Affects the SREBP1a Pathway and Induces Cellular Proliferation. J Mol Neurosci. doi: 10.1007/s12031-012-9890-6

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of PathologyUniversity of KentuckyLexingtonUSA

Personalised recommendations